Market Closed -
Canadian Securities Exchange
12:12:10 08/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.195
CAD
|
-7.14%
|
|
0.00%
|
+34.48%
|
Fiscal Period: Enero |
2022
|
2023
|
---|
Capitalization
1 |
50.77
|
10.88
|
Enterprise Value (EV)
1 |
50.96
|
12.62
|
P/E ratio
|
-2.81
x
|
-0.92
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
21,50,93,845
x
|
72,75,603
x
|
EV / Revenue
|
21,58,80,506
x
|
84,42,474
x
|
EV / EBITDA
|
-5.24
x
|
-1.44
x
|
EV / FCF
|
-87,99,368
x
|
-30,53,399
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
14.9
x
|
12.8
x
|
Nbr of stocks (in thousands)
|
24,887
|
32,476
|
Reference price
2 |
2.040
|
0.3350
|
Announcement Date
|
28/04/22
|
27/04/23
|
Fiscal Period: Enero |
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.236
|
1.495
|
EBITDA
1 |
-0.8402
|
-9.733
|
-8.795
|
EBIT
1 |
-0.8403
|
-9.794
|
-9.192
|
Operating Margin
|
-
|
-4,149.34%
|
-614.69%
|
Earnings before Tax (EBT)
1 |
-1.475
|
-16.47
|
-9.652
|
Net income
1 |
-1.475
|
-15.95
|
-9.143
|
Net margin
|
-
|
-6,755.65%
|
-611.4%
|
EPS
2 |
-0.1168
|
-0.7261
|
-0.3628
|
Free Cash Flow
|
-
|
-5.791
|
-4.135
|
FCF margin
|
-
|
-2,453.36%
|
-276.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
21/05/21
|
28/04/22
|
27/04/23
|
Fiscal Period: January |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
---|
Net sales
|
-
|
0.2043
|
0.2532
|
0.3399
|
0.4305
|
0.4718
|
0.5108
|
-
|
EBITDA
1 |
-
|
-3.548
|
-2.508
|
-2.012
|
-1.658
|
-1.981
|
-1.78
|
-1.459
|
EBIT
1 |
-
|
-3.956
|
-2.647
|
-2.308
|
-1.883
|
-2.354
|
-1.951
|
-1.463
|
Operating Margin
|
-
|
-1,936.52%
|
-1,045.54%
|
-679.13%
|
-437.3%
|
-498.97%
|
-381.96%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-4.178
|
-2.801
|
-2.388
|
-1.623
|
-2.839
|
-1.68
|
-1.151
|
Net income
1 |
-2.946
|
-4.041
|
-2.717
|
-2.299
|
-1.471
|
-2.655
|
-1.68
|
-1.75
|
Net margin
|
-
|
-1,977.74%
|
-1,073.35%
|
-676.51%
|
-341.68%
|
-562.77%
|
-328.95%
|
-
|
EPS
2 |
-
|
-0.1600
|
-0.1100
|
-0.0900
|
-0.0500
|
-0.0900
|
-0.0600
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/12/21
|
28/04/22
|
14/06/22
|
14/09/22
|
15/12/22
|
27/04/23
|
14/06/23
|
14/09/23
|
Fiscal Period: January |
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.19
|
1.74
|
Net Cash position
1 |
0.23
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.0191
x
|
-0.1984
x
|
Free Cash Flow
|
-
|
-5.79
|
-4.13
|
ROE (net income / shareholders' equity)
|
-
|
-945%
|
-649%
|
ROA (Net income/ Total Assets)
|
-
|
-159%
|
-102%
|
Assets
1 |
-
|
10.03
|
8.968
|
Book Value Per Share
2 |
0.0200
|
0.1400
|
0.0300
|
Cash Flow per Share
2 |
0.0200
|
0.0700
|
0.0200
|
Capex
1 |
0.27
|
1.7
|
0.1
|
Capex / Sales
|
-
|
721.09%
|
6.38%
|
Announcement Date
|
21/05/21
|
28/04/22
|
27/04/23
|
|
1st Jan change
|
Capi.
|
---|
| +34.48% | 5.66M | | +41.79% | 50.93B | | -0.56% | 42.12B | | +49.62% | 42.05B | | -7.20% | 29.18B | | +12.59% | 26.02B | | -21.51% | 18.9B | | +6.92% | 13.21B | | +24.91% | 12.17B | | +29.60% | 12.16B |
Other Biotechnology & Medical Research
|